Life Science Trends for 2024

Science and life
122 followers
Xtalks connects professionals in the life science, medical device, and food industries with useful
content like webinars, job openings, articles, and virtual meetings to help you succeed in your
career. This Life Science Focus podcast brings together some of our editorial staff to share
insights into the latest B2B industry news to keep you up to date.
Hello everyone and welcome to the Xtalks Life Science Podcast. I'm Aisha Rashid,
Senior Life Science Journalist at Xtalks.com and this week I'm joined by Sidney Perlmutter
and Vera Kovacevic. Thanks for coming today. So we are officially in 2024 and let's talk about
some of the trends that we can look out for this year in the life sciences. And so there are going
to be a number of trends continuing of course from 2023 in the past couple of years. Of course
the pandemic was the biggest thing that afflicted society in general and of course the life sciences
really catering and ushering in a lot of changes and so those will continue into 2024 as well.
A lot happening in so many different fields from drug discovery to medical device, health wearables
and so it's a very very exciting time as we are on the brink of so many innovations in the life
sciences that we can look forward to. And of course technology really leading and so as we
step into 2024 the life sciences continue to evolve at an unprecedented pace. Again like I
mentioned driven by technological innovation which you know will be leading to deeper understandings
of human biology and drug discoveries and so on and so forth. So let's take a dive into some of
the trends that we can look out for this year. And of course AI and machine learning have been
the biggest one of the biggest stories I think across so many different areas with the advent
of things like chat GPT we're seeing really AI seeping into a lot of aspects in our daily lives
already. So it's a very exciting time and of course these technologies are revolutionizing
research approaches in the life sciences as well. And so since we have a lot of biological data
being accumulated through again innovative technologies in the life sciences there needs
to be technology that can enable the analysis of this vast amounts of data and AI and machine
learning are definitely at the forefront of helping to analyze all of this data which was
previously unimaginable. And so as these technologies mature you know things like AI
will not only help revolutionize drug discovery and development but also aid in predicting disease
patterns and developing personalized treatments. So I actually had the pleasure of speaking to
Joe Varshney who is CEO and founder of Verisim Life. Cut that I didn't speak to her this was a
what do you call it an email interview. Okay step back. So to gain some insights into the world of
AI in the life sciences I contacted Joe Varshney who is the CEO and founder of Verisim Life.
And I was able to get some insights from her in terms of how technologies like AI and drug
discovery and development are revolutionizing the field. So Verisim Life is the developer of
an AI powered drug development platform. And so Dr. Varshney said that since AI is billions of times
faster than humans at analyzing and categorizing data it can help researchers in medical research
and drug development to quickly determine whether certain medicinal compounds will work together or
not. So really this will be right this could revolutionize how drug combinations are evaluated
even before they go into trials. So the idea is that by using AI tools you can predict and analyze
how certain drug combinations may impact individual patients or groups of patients
again even before they enter a trial. So that could definitely be groundbreaking as it helps
remove risk which Dr. Varshney said is one of the biggest barriers to successful cost-effective and
timely drug development. And so you know as we all know like 80 to 90 percent of drugs fail in
clinical trials and that that is staggering. So only 10 percent of drugs that make it through
that get to clinical trials are successful. And so that statistic really again is very staggering.
And AI and technologies like AI and machine learning again have the potential to help improve
these numbers. And so Dr. Varshney said that if a drug's efficacy and potential for adverse events
again talking about risk and side effects can be tested based on AI's broad understanding of human
biology and chemistry even before launching human trials there is a possibility that more promising
drug candidates can be saved from unnecessary failure. So this is pretty exciting because
if you can predict which drugs there are certain times where you may have a drug that
seems promising in pre-clinical studies and then fails in clinical trials but then you also have
the other problem where you may have drugs that may not seem so promising in pre-clinical trials
in animal models or in in vitro studies but perhaps that drug you know was cut at that point
but perhaps it might have success in human trials. So you may lose those drugs at the pre-clinical
stage because they don't seem to be promising. And so technologies like AI the idea is that they can
really pinpoint and better stratify or better predict which drugs may do well in human trials.
So that's really exciting again the idea is to reduce failures and also significantly cut down
current drug development timelines which on average have been about 10 years or so. So that
is also an area where AI technologies can help as well. So regulatory bodies are also taking note of
the applications of AI in drug development. So in 2023 the FDA actually issued a request for
industry comment on the integration of AI in drug and biologics development. And this is probably
because the FDA received more than a hundred investigational new drug submissions in 2021
that included AI and machine learning components. So again we're really seeing these technologies
in drug development and the FDA has to is taking notice because they're receiving all of these
applications with their use in them. And so Dr. Varshney said that in 2024 she believes that
we could see an increase of these INDs with AI and machine learning components to increase to
around 400 applications. So another important challenge is that enhanced drug candidates may
not fare well in the clinic and Dr. Varshney said that this was seen in 2023 because a lot of the
early application of AI has been focused on molecule discovery with far less adoption of
its potential to guide translational research. So she says that in 2024 pharma companies and
emerging biotechs will improve candidate safety profiles and reduce our off-target effects
by exploiting predictive intelligence unlocked by AI. So I just wanted to get your thoughts on
this kind of exciting cusp that we're at with AI which seems to be so far
reaching. And of course in drug development, drug discovery and also making its way into
clinical trials. So through the whole drug development process this could really be a game
changer. Yeah for sure. I think like in all stages of drug discovery and development
you know companies like Verisim Life are trying to incorporate AI to just not only make the process
faster but honestly like more effective too because they can analyze large amounts of data
faster. And what I really think is that it seems like Verisim Life is focusing a lot on you know
analyzing how drug combinations may impact individuals. So that's extremely beneficial
for like cancer therapy. As you know like lots of cancer therapeutics are given in combination
with something else right. So I think that has huge promise for oncology treatment and something
that what you were talking about Aisha was kind of reminded me of that concept of in silico clinical
trials. Have you heard of that? Yeah yeah absolutely. Yeah where they're trying to model like how a drug
is going to impact like a virtual human organ system right. And so that's extremely helpful
for like rare disease drugs where it's really hard to recruit patients and you can get a lot
of insights that way. So really all along like the whole discovery and development pipeline they're
trying to implement AI in some way. So I think it's really cool and yeah definitely a top trend
for 2024 for sure. And I think you chose like a great person to interview too. Yeah absolutely. I
we've had before I mean like you mentioned in silico modeling computational modeling of drugs
but I think with the incorporation of AI into the that kind of modeling it's just going to take it
to the next level for sure. And yeah I mean are you guys like surprised that 90 percent of drugs
fail in clinical trials? Like that again that statistic is is eye-opening and I think there
hasn't been a lot of changes really in drug development I think for decades and I think
it's due time. Yeah I think this century will be like biology's century and I think that
hopefully that number will go down with the use of like simulation and AI. But yeah 90 percent is a
lot of drugs. It's it does sound like a lot especially for the amount of drugs new drugs
that do come out each year. Makes you think of you know how many potential new drugs could have
come out during a certain time period. But I also think that it's a good thing in a sense just
because if there wasn't as much you know vetting and you know procedure that needed to be followed
maybe there would be more drugs on the market that weren't you know safe. But yeah it's it's
a large number and I think cutting it down would certainly save a lot of money a lot of resources
a lot of people's time and and you know make things make things safer as well. So I'm surprised
but I'm also not surprised. Yeah sort of two minds on that. Absolutely I think those timelines are
important as well. Financial considerations. So if 90 percent of drugs are failing just imagine
the financial costs to the industry in general like how it takes. I think I was reading the
other day I think it takes about one or is it around two billion dollars to develop a drug
on average. So there is a lot of money at stake and if technologies like AI can can help bring
those costs down I think it's a win-win because we're you know at the end of the day getting drugs
to to patients and making sure that patients can access those drugs financially is a huge
consideration. All right so another trend that we will see continuing on into 2024
is the development of CRISPR-based gene editing therapeutics. So one of the big stories in 2023
was that we had the very first approval of a CRISPR-based gene therapy so for sickle cell
disease and that approval was awarded to Virtex Pharmaceuticals and CRISPR Therapeutics.
So the two companies jointly developed Cascavi or XSL and so the companies received FDA approval
for that last year and so that was a huge story. And CRISPR Therapeutics of course
is co-founded by Emmanuel Charpentier who was one of the co-discoverers of CRISPR technology along
with Jennifer Doudna and of course these scientists received the Nobel Prize in 2021 I believe
for their discovery of CRISPR. And now to see you know taking their discovery of CRISPR
but the biology of CRISPR and now translating that into therapeutics and treatments I think
it is very very exciting. And so you know seeing the very first CRISPR-based therapy had receiving
approval was a big milestone last year and we're just going to be seeing even more applications
for CRISPR-based treatments in the coming year for regulatory approval. And so there are several
companies working in the space of CRISPR-based treatments and some notable ones include
Editus Medicine and this company is focused on developing therapies for genetically defined
diseases. And of course CRISPR is a gene editing technology and it's very specific so that's why
it's a very powerful tool in terms of the potential for developing therapies for genetic diseases.
So Editus again is working on CRISPR-based treatments for conditions such as a rare
inherited form of blindness and blood disorders as well. And then there is Intelia Therapeutics
which is notable for its in vivo CRISPR gene editing approach and the company is working
on treatments for diseases like trans-thyritin amyloidosis which is a serious condition affecting
the liver and nervous system. And then you have Beam Therapeutics which is a company focused on
base editing which is a more precise form of CRISPR editing that allows for single DNA-based
changes without making double-stranded breaks in the DNA. And then we have Caribou Biosciences so
this company is founded by one of the other co-inventors of CRISPR Jennifer Doudna and
so her company is working on engineering immune cells using CRISPR technology for potential cancer
therapies. And then Precision Biosciences is a company that uses a proprietary genome editing
method that they've developed to develop treatments for cancers and genetic disorders. And of course
cancers and genetic disorders as I mentioned are the two biggest areas or applications
for CRISPR technology but of course it can definitely be used to develop therapies in
other diseases as well. And so these companies are at various stages of research and clinical trials
with their compounds and again like I mentioned in 2024 we're likely to see more advancements
and potentially new CRISPR therapies emerging from these companies and there are even more in
the field these are just a couple or several that I mentioned here. So yeah I just wanted to get your
thoughts on CRISPR and how it's really revolutionizing cell and gene therapies the field
in general because before CRISPR we had a big focus on immunotherapies in cancer but CRISPR
technology seeing it just within a decade going from a proof of concept thing in the lab to making
it to the clinic and potentially treating patients now with the approval as I mentioned for the very
first therapy that we saw last year. So yeah I just wanted to get your thoughts on this new technology
and also gene editing I think decades before we're actually seeing it today but if we rewind back
there were so many there have always been concerns about technologies involving genetics in terms of
the ethical implications and what that means in terms of you know today we're also accumulating
so much genetic data and so there are a lot of ethical concerns around that as well and also
technologies like CRISPR gene editing technologies what if they fall into the wrong hands and so there
were so many considerations in this area so just wanted to get your thoughts on it.
Yeah Aisha well to talk about your first point so yes the first CRISPR-based therapeutic was
approved last year CASGEVI that was developed by Virtex Pharmaceuticals and CRISPR Therapeutics
and that was given for sickle cell disease and then I just saw today that Virtex Therapeutics
got FDA approval for CASGEVI again except this time for the treatment of transfusion dependent
yes okay nice yeah so it I know that you mentioned last year when you were
writing about the story that you know it's also under consideration for this other rare disease
so now they got it approved just today so yeah I think it's really exciting and
certainly more FDA approvals will come probably even this year and next year but to talk more
about your second point like yeah there is a big concern with like off-target effects
of these like you know CRISPR-Cas9 therapeutics because yes they're designed to target a specific
DNA sequence and correct for it for these genetic diseases but for example what if they
accidentally edit other parts of the genome right and I know there's so many ways that
the companies can test for this in their therapeutic development and they're doing so
but there's always a concern right and I think oh from what I also heard like the rare disease
patients are really eager to get these technologies and these new therapeutics to them because it
would potentially be like a one-time treatment that could be life-changing for them right so
I've heard that the rare disease patients are really eager and brave to to want to try out
this new technology and it's because it's so promising so regarding ethical concerns
what what what kind of what do you mean like ethical concerns with these technologies can
you give some examples? Yeah I think it's kind of an older topic but I think it's still relevant
but in terms of designer babies and all of those concepts we used to hear in the past
you know or people using genetic technologies for you know not so good things
manipulating genetics and things like that and using them potentially as weapons and again a lot
like things that are so far-fetched but I mean they they have been of concern but I think
that was back when we didn't have any gene therapies approved but now that we do I think
the climate kind of has sort of changed because I don't really hear a lot about all of those
sort of Frankensteinian kind of you know concerns really so maybe now that we are here
with actual gene therapies and approved maybe the climate has changed and Vera to your point yeah
you know a lot of rare disease patients advocacy groups as well of course for a lot of these
patients like they have like a lot of these rare diseases have no treatments and so these patients
are hate to say the word desperate but they're they really have they have no options in a lot
of cases and so there has been such a great push to get novel treatments and to get treatments
to these patients and it's been a concerted effort between industry academia patient advocacy groups
and patients themselves so to see these therapies coming to light I think it's credit to all of
these players and I think you know when I've spoken to industry experts this is another theme
that ties in with the approval of a lot of these new and novel therapies that we're seeing is that
it's been a concerted effort that has involved multiple stakeholders so I think you know the
patient centricity aspect of it is really important seeing a lot of these their therapies come to light
yeah I was when you were talking about the like ethical concerns I was thinking like
of course something like this could be abused or misused and that yeah that designer baby
like concern still still is like a concern in certain ways but I don't think that
it should discourage you know actual progress in terms of using CRISPR in that way so
yeah I mean is is it I'm just assuming that it's not really at the forefront anymore but like is
is the you know are these ethical concerns like still prominent in in or prominent at all in in
this area of gene editing or were there ever really ethical concerns in terms of you know
providing patients with rare diseases some some sort of help like I don't I don't even see how
there could be ethical concerns there was it just the use of that technology it was yeah it was more
of the abuse of the technology and I believe Jennifer Doudna again one of the co-inventors
of CRISPR at length actually at some conference or a meeting she she was at discussing the ethics of
genetic technologies like CRISPR so it definitely still is a concern but of course when we're
talking about the therapeutics aspect of it I mean this is game-changing and although to your
point Vera yes there are still safety concerns with a lot of cell and gene therapies because
of off-target effects and in fact the FDA actually has launched an invest an investigation
looking at the cancer risk linked to CAR T-cell therapies so that was in December last year so
there are concerns again there have been rare cases where CAR T-cells have been linked to the
potential risk of cancers and again owing to off-target effects and things like that so
there are concerns but you know the fact that we do have regulatory bodies you know taking these
concerns and looking at these risks seriously I think is important and yeah as with any new
technology with any new drug I think you need to have that oversight happening and it's
obviously it's a good thing that the FDA has taken notice but again we've had early iterations
of CAR T-cell therapies gene therapies and CRISPR and so these are only going to get better and
better the technologies themselves and I think those risks and safety concerns will be addressed
as the technologies get better and better okay let's take a look at the last trend that I talked
about in my piece and this is about next-gen health wearables with medical accuracy so the
global wearable medical devices market size was valued at 73.77 billion dollars in 2023 and it's
projected to grow to 428 billion by 2030 so that is quite staggering and so the rapid proliferation
of wearable technology for monitoring health indicators again has remained a steadfast trend
for the past decade or so and it will continue to be a major trend in the life sciences this year
and beyond so despite the massive continuing growth the industry actually appears to have
reached a bottleneck of sorts because the limitation of a lot of these health wearables is that
they are for health and wellness purposes but they're not medically certified devices in most
cases so if you think about your Fitbit or your your Apple iPhone or and you know tracking your
steps all of these are sure monitoring and tracking your different health indicators but
they're not medically accepted metrics and they don't provide medical accuracy and so to address
this a segment of health wearable developers are focusing now on designing devices with medical
relevance and applications so that if you do have a device you can actually extract medically
relevant information that you can discuss with your doctor and then take appropriate medical
interventions based on the data that's accumulated. So I had the pleasure of speaking to Dr. Anna
Barnacka who is the CEO and founder of MindMics which is a company that's developing a wireless
earbud heart health monitor and again I would suggest everybody check out this company because
I think what they're doing is very innovative very very cool and so Dr. Barnacka told me that
this is an exciting time for the health wearables industry and she said that her company MindMics
is focused on developing a medically accurate GPS for health so she was talking about how we have
a GPS to help us navigate to different locations and so it's also important to have the same thing
for our health. So Dr. Barnacka actually has a very interesting story so and background she was
actually a NASA Einstein fellow at Harvard University and her research involved looking
at black holes with precision instruments and so working as an astrophysicist she said that she was
experiencing burnout and wanted to take a look at her health but she looked around and and saw that
there were no wearable technologies in the market that were medically accurate enough and so she
decided to do something about it and founded MindMics to take health monitoring to the next
level. So Dr. Barnacka says that with the strong consumer market that is now demanding more with
respect to user experience and medically relevant insights what we need now is the technology that
will be able to give us medical accuracy for wearable technology. So for heartbeat measurements
with conventional photoplethysmography or PPG optical technology so that's the technology
that's used in most current health wearable devices like watches a lot of information is lost
so to address this MindMics uses in-ear infrasonic hemodynography technology
which in simple terms is based on the detection of sound waves in the ear canal produced by blood
flowing through the vascular system and so the sound waves that are propagated to the ear canal
have very little distortion of the signal giving heartbeat measurements as accurate as invasive
cardiac catheterization procedures. So the problem was though Dr. Barnacka said that in
developing this technology since these sound waves are below 20 hertz existing technologies
and industry standards were not equipped to detect sound waves below this threshold so the company
had to innovate building an infrasonic lab to validate and build standards to be able to evaluate
the components microphones involved and all of that with this earbud in this range so below 20 hertz
and fittingly she said that it was essentially a black hole below 20 hertz so they were able to
successfully develop this product the system and again a whole lab infrastructure around it to be
able to validate this device and to be able to detect sound waves below 20 hertz and data from
the earbud monitor is then sent to the cloud where it's stored and analyzed providing real-time
results and actionable insights. So again this is monitoring your heart health by using sound waves
detected in your ear which I thought was super cool very innovative the technology was there but
again MindMics took it to the next level by being able to really hone in on the threshold below 20
hertz and to really take that technology and again it's comparable to invasive cardiac procedures
so in terms of the data that you get from it so a very robust heart monitoring system indeed.
So Dr. Barnatska also noted that an important trend for the industry is to think about how to
make preventive health a good business model so she said that current models are focused on
treating diseases but long term prevention is a key way of course to reduce costs
but unfortunately she said that as of today it's still difficult to convince payers that prevention
is where it's at and so she said that there was a lot of work to be done on that side because it's
better to work on prevention than to cure or treat diseases but again that business model isn't there
and she said that we have to shift that mindset which I thought was very enlightening and of
course an important aspect for sure. So yeah I think really fundamental to many of the trends
and innovations that we're going to see in 2024 as we talked about is the adoption of
cutting-edge technologies that will enable revolutionary discoveries and solutions
and I think this technology this device from MindMics is definitely an example of this.
So I just wanted to get your thoughts on this technology health wearables as a market and in
general if you use health wearables in your life and are you also ready to move into the next
dimension of medically accurate health wearables? Well I personally don't use any health wearables
but if I do I would like to know that they've been like FDA approved or Health Canada approved
for that specific purpose or monitoring goal just because to me that adds like an extra layer of
like validity and I just feel like I can trust it more. So to me that's important if I was to
use one like I want to make sure that it's been approved for that purpose but I think like yeah
they're becoming quite popular and I think it's mostly because of like the Apple watch.
Maybe do you guys have any other companies or watches or wearables at the top of your head
that you can share? I mean Fitbit is like the biggest company I believe still in the area but
yeah I personally actually don't use any health wearables either but again because I also just
personally saw it as you know as a which they are currently mostly as just health and wellness you
know trackers that will track how many steps you've taken in a day which is all fine and
great but do we really know what those metrics translate into medically like if you you know
10,000 steps what does that mean for your heart what does that mean for your respiratory system
like we don't really have we don't have that information so we have all of this data that
we're collecting but we can't really do anything with it and we don't have those medical insights
to be able to make decisions so I think the industry is taking a leap towards that next
step which I think is really great to see because now you can actually take health indicators and
measures that you've collected and actually take them to your doctor and discuss them
it's like now it's like if you take your 10,000 steps to your doctor they're not going to really
be able to give you anything and so I think the idea really is to or the idea is to have medically
accurate information and with that like you said Vera to have FDA approvals and regulatory approvals
backing a lot of these devices or the next gen of devices that will be coming out
and also I found what was very interesting what was very interesting that Dr. Barnatska
mentioned was about prevention over treatment and I think that's often overlooked a lot
where the industry a lot of industries and the life sciences are very very focused on
treatment and drug discovery development which is of course important but there are you know
what are the strategies and approaches that we can develop to address prevention and I found
her insights on that topic to be very interesting in that we don't have business models because
essentially at the end of the day from an industry perspective it is a business and so prevention
can become a business which I thought was very cool so there is money to be made you know in
every aspect and prevention you know can be one of them and that's important for for us and for
patients at the end of the day so I thought that was an interesting insight what do you think about
that yeah I love that insight I do think that the the way the business model is organized now
not just in the U.S. but in Canada it's like it's up to the patient to go and say oh I'm due for my
colonoscopy or I'm over this age now I can get screened for this or oh it's time for my annual
physical exam right it's always on the patient to take the initiative and sometimes I feel like
if they were contacting us and telling us oh you're due for I don't know a pap smear I know
that in Ontario they started to do that to women now but if they were to do that for everyone and
you know just like if they were to take the initiative I feel like patients would listen
and follow instead of the patient has to take initiative for their own health and many times
when you yourself have to take the initiative typically you won't go unless you feel like
there is a problem and at that point it may be a little bit late and you may have to go on treatment
what do you guys think yeah I totally agree I think if they were as persistent
as dentists in terms of getting you to come to appointments
then it could be a lot more effective and yeah I think prevention even starts at like
oh my goodness there's so many levels to it I think it starts at like just basic education as
well like even when even when you're young in elementary and grade school and high school and
whatnot I think you know because learning obviously you can't learn about everything
that could possibly go wrong with you but I think like teaching the importance of checking in like
having you know annual checkups and taking certain you know tests at certain periods in your life
like I think that's so important too because I think yeah we as patients find out that we need
to do a lot of these things either by happenstance or we're told by like friends or something comes
up and we have to go to the doctor rather than like knowing that these are the things that we
need to do so yeah I agree and there is a lot of money to be made and on the preventative side as
well so I don't think it's there's you know the business of health care needs to worry about
yeah as well because there's there's definitely money to be made and yeah I definitely agreed and
I think yeah things are getting a lot better in terms of screening you know you will get
things in the mail about okay you're due for this test or that test but I think there's still a
disconnect in in terms of like you know patients not maybe fully understanding why they need to
get that test you know and what it's going to do like for example a colonoscopy it's probably one
of the best preventative diagnostic treatment slash I'd say even treatment because you know
if you have polyps in your colon those can be taken out removed right during the colonoscopy
and so you can prevent those from potentially becoming cancer later down the line and I don't
think a lot of patients know that right so I think there's a real disconnect between education and
the tools and screening tools that we have and I think that needs to improve for sure and in the
context of these health wearables the next gen health wearables that we're kind of talking about
is that they can help in a lot of these preventative measures you know if you see something
abnormal on your heart monitor your earbud heart monitor you you'll be you know alerted and you can
take action to do something about it so I think that's going to be very powerful and really putting
the power in patients hands to really take action and have agency over their health.
All right so those that was an overview of some of the of some of the trends that we can expect
in 2024 and of course there are a lot more exciting things that we can expect in the coming
years in the life sciences across the pharmaceutical biotech and medical device
sectors. All right and so that brings us to the end of the life science podcast I hope you like
today's show don't forget to rate review and subscribe if you did. Thank you everyone and
see you all next week. Bye for now. Bye. Thanks for listening to the Xtalks life science podcast.
If you enjoyed our discussions today please share the episode with your friends and colleagues
and be sure to subscribe in order to be notified when a new episode is released. To join in on the
discussion you can find Xtalks on social media, email podcasts at Xtalks.com or comment on the
articles directly. Links are in the show description. Take a moment to join our community at
Xtalks.com to get access to everything we have to offer including webinars, job listings, virtual
meetings, articles and more. The views and opinions expressed in the podcast are those of the speakers
sharing them. They should not be taken as professional advice and do not necessarily
reflect the policy or position Honeycomb Worldwide. For further information email us at
podcast at Xtalks.com. Thanks for joining us and we'll see you next week.
